Compare MNOV & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNOV | EPM |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 143.0M |
| IPO Year | 2004 | 1996 |
| Metric | MNOV | EPM |
|---|---|---|
| Price | $1.42 | $3.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $8.25 | $4.94 |
| AVG Volume (30 Days) | ★ 786.3K | 396.5K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 13.08% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,360,807.00 | ★ $43,229,621.00 |
| Revenue This Year | $78.20 | $3.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $3.19 |
| 52 Week High | $3.90 | $4.99 |
| Indicator | MNOV | EPM |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 52.57 |
| Support Level | $1.29 | $3.46 |
| Resistance Level | $1.48 | $3.78 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 1.55 | 71.25 |
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.